Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Burkitt's lymphoma  (1)
  • Chronic myelogenous leukemia  (1)
  • 1
    Electronic Resource
    Electronic Resource
    Springer
    Annals of hematology 79 (2000), S. 345-354 
    ISSN: 1432-0584
    Keywords: Key words Management ; Chronic myelogenous leukemia ; Autograft ; Allograft ; Bone marrow transplantation
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The management of chronic myelogenous leukemia (CML) has become complex due to the availability of improved diagnostic procedures and life-prolonging or even curative treatment strategies that are more successful the earlier they are applied in the course of the disease. This is true for allogeneic bone-marrow transplantation, treatment with interferon α (IFN) and Philadelphia-negative stem-cell collections for autografting. Outcome differs according to risk profiles of patients at diagnosis. In addition, molecular techniques for the detection of the BCR-ABL fusion gene or its products, such as the reverse-transcriptase polymerase chain reaction (PCR), Southern blot analysis, or fluorescence in situ hybridization, facilitate accurate diagnosis and the monitoring of residual disease. They allow the individualization of treatment such as early infusion of donor lymphocytes if molecular relapse is detected after allografting, or discontinuation of IFN in the presence of very low BCR-ABL transcript levels). The availability of real-time PCR devices further improves and accelerates the diagnosis and monitoring of residual disease. This article addresses recent developments in drug therapy and allografting, including treatment intensification with low-dose ara C or intensive chemotherapy followed by autografting, introduction of new drugs (such as homoharringtonine or tyrosine kinase inhibitor STI571), progress with unrelated donor transplantations, use of peripheral blood stem cells for allografting, and transplantation without myeloablative conditioning. Tradeoffs between the treatment options will be discussed in the context of the evidence-based guidelines for treating CML, as recently published by the American Society of Hematology. Finally, the new competence network on acute and chronic leukemias will be introduced.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1569-8041
    Keywords: Burkitt's lymphoma ; c-myc ; PCR ; translocations
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: Burkitt's lymphoma (BL) and B-ALL are characterized bychromosomal translocations juxtaposing the c-myc gene on chromosome 8to one of the immunoglobulin loci. Translocations involving the immunoglobulinheavy chain (IgH) on chromosome 14 are found in approximately75%–90% of these tumors. The breakpoint regions arelocated over a wide range on both chromosomes. Patients and methods: To detect the translocations, we developed aPCR method to generate long products. After extraction of genomic DNA (QiaAmpSystem,Qiagen, Hilden, Germany), DNA was amplified using a mixture of Taq andPwo polymerases (Boehringer Mannheim, Germany). Several primer pairs from theSµ, JH, CH1 and the Cα regions on IgH and from exon 1 and intron 1of the c-myc gene were tested in each patient. Results: Lymphoma cells from 20 children with Burkitt's lymphoma andB-ALL characterized by FAB-L3 morphology were examined. In 11/20 patients,recombinations between chromosomes 8 and 14 could be detected with our primerpairs. PCR products from 800 to 3700 bp in length were obtained reproducibly.After amplification, the products were characterized by restriction enzymedigestion, hybridization, and in part by direct sequencing. Conclusions: This PCR-based method will allow us (1) to determinethe localization of chromosomal breakpoints in primary tumor material, (2) toinvestigate whether distinct breakpoints are associated with treatmentoutcome, and (3) to detect the presence of minimal residual tumor cells duringor after therapy.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...